Diabetes · Phase 3
AWARD-7: diabetes with chronic kidney disease
What was tested?
Dulaglutide versus insulin glargine as basal therapy, with insulin lispro in all groups. ↗
Registered primary question: Change in HbA1c at week 26. ↗
What the reviewed report found
Journal year 2018 · Article summary reviewed 2026-09-15
Dulaglutide met the prespecified noninferiority criterion for glycated hemoglobin change at 26 weeks. At 52 weeks, estimated filtration rates were higher with dulaglutide; nausea and diarrhea were more frequent.↗
Keep in context: The study continued for 52 weeks, but the primary comparison was glycemic control at week 26. Kidney measurements were secondary outcomes. ↗↗
Participants, design, limitations and sources
Registry snapshot
- Registry enrollment
- 577 · reported actual
- Registry status
- Completed
- Allocation and masking
- Randomized · Open label
- Design
- Parallel
- Eligible ages
- 18 Years; maximum not specified
- Registry results
- Posted in this snapshot
Registry source ↗ · Updated 2019-09-19; retrieved 2026-09-20. Registry enrollment is not necessarily the analyzed sample in a publication. Posted registry results and published article results are separate.
AWARD-7: diabetes with chronic kidney disease
- Design in the report
- An open-label randomized trial compared dulaglutide with insulin glargine, with insulin lispro in all groups, over 52 weeks.↗
- Participants in the report
- The study randomized 577 adults with type 2 diabetes and stage 3–4 chronic kidney disease.↗
- Limitations
- Kidney measures were secondary outcomes. This trial cannot establish a general prevention claim for kidney failure or isolate the effects of background insulin treatment.↗
This reading covers the article abstract and record metadata. Read its preserved Human Evidence Review →
How the study identity and sources were checked
Study context checked 2026-09-20. Existing article summaries keep their original review dates. This is a selected study reading, not a complete literature or full-text appraisal.
Registry
A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD) ↗
Protocol identifier: 13798. Sponsor: Eli Lilly and Company.
Retrieved 2026-09-20; SHA-256 5e189681a5b23fa2dece5e40c2842c61bb7ff3f5d192038261bfc801860ec6b1.
PMID 29910024
Exact trial identity is declared in PubMed’s ClinicalTrials.gov databank field. The registry independently labels this reference DERIVED. These source labels do not establish that every result in a paper applies to this trial.
Identity metadata retrieved 2026-09-20. EFetch batch XML; locate MedlineCitation/PMID 29910024. SHA-256 0e6795be99af1c93f3a3e2726fc8a17152661ca29e8dead110bff36feb856127.
Scientific summary uses the original 2026-09-15 source snapshot: SHA-256 31bd83dd9c06f67f4c208db9e37ece0be0360231598fbfc2ad6d135281db9297.